SCHEMBL3834407

SCHEMBL3834407

CCCc1nc(SC2CCC(C(=O)O)CC2)c(OC(=O)O)n1Cc1cc2c(cc1Cl)OCO2

nearest known ligand 0.64

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
EDNRA P25101 2/20 0.64
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
HPGD P15428 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
CYP3A4 P08684 3/20 0.32
CYP1A2 P05177 2/20 0.32
CYP2D6 P10635 2/20 0.32
CYP2C19 P33261 2/20 0.32
AGTR1 P30556 1/20 0.32
AGTR2 P50052 1/20 0.32
SLC22A12 Q96S37 1/20 0.31
MCHR1 Q99705 1/20 0.31
PTGES O14684 1/20 0.30
EDNRB P24530 1/20 0.30
LMNA P02545 1/20 0.30
MAPT P10636 1/20 0.30
CYP2C9 P11712 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3839183 0.90 EDNRA (0.78) EDNRAKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL3839302 0.89 EDNRA (0.56) EDNRAKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL3834405 0.87 EDNRA (0.81) EDNRAKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL3837170 0.87 EDNRA (0.58) EDNRAKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL7501806 0.87 EDNRA (0.57) EDNRAKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL3840862 0.81 EDNRA (0.44) EDNRAKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL7503953 0.80 EDNRA (0.53) EDNRAKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL6159408 0.79 EDNRA (0.52) EDNRAKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL7506376 0.79 EDNRA (0.51) EDNRAKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL3835438 0.78 EDNRA (0.69) EDNRAKDM4EALDH1A1HPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0861247-B1 NOVEL IMIDAZOLE N-BENZYLDIOXOL DERIVATIVES, METHOD FOR PREPARING SAME, RESULTING INTERMEDIATES, PHARMACEUTICAL COMPOSITIONS AND USE OF SAID DERIVATIVES AS ENDOTHELIN ANTAGONISTS AVENTIS PHARMA SA (FR) 2009-10-07 EP claimed